// App-Quantinova.ai

: MicroRNAs (miRs) as biomarkers of resistance to trastuzumab in HER2-positive oesophago-gastric cancer: Sub-study within the Planning Treatment for Oesophago-Gastric Cancer—A Randomised Maintenance Therapy Trial (PLATFORM).

Researchers

Presenter

  • Hazel Lote

Principal Investigators

  • Florentia Mousoullou

  • George Vlachogiannis

  • Caroline Fong

  • Laura Satchwell

  • Clare Peckitt

  • Ruwaida Begum

  • Shannon Kidd

  • Susan Cromarty

  • Anderley Gordon

  • Charlotte Victoria Fribbens

  • David J. Watkins

  • Sheela Rao

  • Ian Chau

  • Naureen Starling

  • David Cunningham

  • Nicola Valeri

Medical Centers

  • The Royal Marsden Hospital, London, United Kingdom

  • The Institute of Cancer Research, The Royal Marsden NHS Foundation Trust, Sutton, United Kingdom

  • The Royal Marsden Hospital NHS Trust, London and Sutton, United Kingdom

  • Department of Surgery & Cancer, Imperial College London, London, United Kingdom

  • Imperial College, London, United Kingdom

  • The Royal Marsden Hospital NHS Foundation Trust, London & Surrey, United Kingdom

Locations

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Gastric Cancer

Biomarkers

  • Human epidermal growth factor receptor 2

Drug/Treatment

  • Trastuzumab

  • miR-16

Outcome

  • N/A

Study Design

  • Randomized

  • Open Label

  • Multicenteric

  • Prospective

Phase

  • II

Study Id's

  • NCT02678182

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved